Literature DB >> 17553806

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.

Olivier Dormond1, Joren C Madsen, David M Briscoe.   

Abstract

Recent studies have determined that mTOR mediates the activation of the protein kinase Akt in several cell types, but little is known about the association between mTOR and Akt in vascular endothelial cells. Furthermore, the functional significance of mTOR/Akt signaling has not been characterized in the endothelium. In these studies we treated endothelial cells with the mTOR inhibitor rapamycin, and we found that it decreases Akt phosphorylation and activity, as determined by phosphorylation of its substrate glycogen synthase kinase-3. This effect of rapamycin on Akt phosphorylation could not be demonstrated in endothelial cells transfected with a rapamycin-resistant mTOR construct. Also, in the presence of rapamycin, vascular endothelial growth factor, tumor necrosis factor, and insulin failed to phosphorylate Akt, further indicating that mTOR regulates Akt activation in endothelial cells. The activation of Akt is well established to mediate pro-survival signals. In part this is mediated via the phosphorylation and inactivation of the pro-apoptotic Akt substrates Foxo1 and Foxo3a. We find that rapamycin totally blocks vascular endothelial growth factor and Akt-inducible phosophorylation of these transcription factors in endothelial cells. Furthermore, inhibition of Akt activity by rapamycin increased the number of endothelial cells undergoing apoptosis after serum withdrawal as well as after stimulation by vascular endothelial growth factor or tumor necrosis factor. Taken together these observations demonstrate first, that mTOR regulates the phosphorylation and activation of Akt in endothelial cells and, second, that a major effect of mTOR inhibition in endothelial cells is to suppress Akt-inducible pro-survival signals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553806      PMCID: PMC3383050          DOI: 10.1074/jbc.M700563200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Will mTOR inhibitors make it as cancer drugs?

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

Review 2.  Role of Akt signaling in vascular homeostasis and angiogenesis.

Authors:  Ichiro Shiojima; Kenneth Walsh
Journal:  Circ Res       Date:  2002-06-28       Impact factor: 17.367

3.  Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells.

Authors:  F Tremblay; A Marette
Journal:  J Biol Chem       Date:  2001-08-09       Impact factor: 5.157

4.  NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.

Authors:  O Dormond; A Foletti; C Paroz; C Rüegg
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

5.  Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B.

Authors:  Michael P Scheid; Paola A Marignani; James R Woodgett
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

6.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

7.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors:  Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

8.  Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis.

Authors:  Subham Basu; Nicholas F Totty; Meredith S Irwin; Marius Sudol; Julian Downward
Journal:  Mol Cell       Date:  2003-01       Impact factor: 17.970

9.  mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.

Authors:  Diane C Fingar; Celeste J Richardson; Andrew R Tee; Lynn Cheatham; Christina Tsou; John Blenis
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation.

Authors:  Jing Yang; Peter Cron; Vivienne Thompson; Valerie M Good; Daniel Hess; Brian A Hemmings; David Barford
Journal:  Mol Cell       Date:  2002-06       Impact factor: 17.970

View more
  66 in total

1.  Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells.

Authors:  Jacinta Serpa; Francisco Caiado; Tânia Carvalho; Cheila Torre; Luís G Gonçalves; Cristina Casalou; Pedro Lamosa; Margarida Rodrigues; Zhenping Zhu; Eric W F Lam; Sérgio Dias
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Protection of porcine endothelial cells against apoptosis with interleukin-4.

Authors:  Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

3.  Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate.

Authors:  D Davila; N M C Connolly; H Bonner; P Weisová; H Dussmann; C G Concannon; H J Huber; J H M Prehn
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

4.  Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice.

Authors:  Haihong Zong; Claire C Bastie; Jun Xu; Reinhard Fassler; Kevin P Campbell; Irwin J Kurland; Jeffrey E Pessin
Journal:  J Biol Chem       Date:  2008-12-08       Impact factor: 5.157

5.  Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

Authors:  Heloisa Veasey Rodrigues; Danxia Ke; JoAnn Lim; Bettzy Stephen; Jorge Bellido; Filip Janku; Ralph Zinner; Apostolia Tsimberidou; David Hong; Sarina Piha-Paul; Siqing Fu; Aung Naing; Vivek Subbiah; Daniel Karp; Gerald Falchook; Razelle Kurzrock; Jennifer Wheler
Journal:  Invest New Drugs       Date:  2015-04-24       Impact factor: 3.850

6.  A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Future Neurol       Date:  2012-11

7.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

Review 8.  Effect of antibodies on endothelium.

Authors:  X Zhang; E F Reed
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

9.  Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation.

Authors:  Anwer Habib; Vinit Karmali; Rohini Polavarapu; Hirokuni Akahori; Masataka Nakano; Saami Yazdani; Fumiyuki Otsuka; Kim Pachura; Talina Davis; Jagat Narula; Frank D Kolodgie; Renu Virmani; Aloke V Finn
Journal:  J Am Coll Cardiol       Date:  2013-03-05       Impact factor: 24.094

10.  Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cells.

Authors:  Megan E Cavet; Elaine M Smolock; Oktay H Ozturk; Cameron World; Jinjiang Pang; Atsushi Konishi; Bradford C Berk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-21       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.